Abstract
Introduction
In spite of the fact that radioiodine has been employed for the treatment of hyperthyroidism for over sixty years, and although numerous studies all over the world seem to have provided a comprehensive view of various aspects of this therapy, a uniform standard of procedures has not been developed as yet. The lack of agreement as to radioiodine treatment of hyperthyroidism frequently results from the fact that specialists do not make adequate use of knowledge concerning the pathophysiology of the thyroid gland or data on the interaction of ionising radiation with organic matter. Admittedly, we still do not have a method to assess the radiosensitivity of the treated gland, but many hospitals -both in Poland and abroad -neglect other, equally important and easily measurable, parameters such as:
-concentration of thyrotropin (TSH) in the blood serum of patients with toxic nodular goitre before radioiodine administration, crucial for stimulation of extranodular (non-autonomous) iodine uptake by thyroid gland tissue [1] [2] ; -thyroidal iodine uptake, with particular attention to the dynamics of its change, whose indicator is the effective half-life of 131 I (T eff. ) [3] [4] . The volume of the gland assessed by USG was calculated using the usual formula for the volume of a spheroid [9] : 
Statistical analysis
All statistic analyses were performed using the software package Statistica 9 (Stat Soft, Kraków, Poland).
General comparison of the two (ATN, TMG) groups in terms of gender, euthyroidism, hypothyroidism and hyperthyroidism after 1, 3 and 5 years from the commencement of therapy was performed using the c 2 test, whereas the Mann-Whitney test was used for comparison in terms of age.
In order to assess the proportion of euthyroid, hypothyroid and hyperthyroid patients depending on sex, age, thyroid gland volume, radioiodine effective half-life and uptake in nodule, the c 2 test was employed separately for both groups.
Friedman's test was used to estimate the difference between fT 4 , fT 3 , TSH levels at 2 weeks before treatment and those observed in the subsequent months after 131 I administration.
Moreover, the logistic regression model was used to evaluate the degree to which independent variables (gland volume, T 24 , T eff. , radioiodine uptake in nodule) affected the likelihood of recovery (i.e. restoring euthyroidism). The influence of the same variables on the probability of hypothyroidism was assessed analogically.
Results Table 1 presents a summary of the characteristics of the patients who were included in the sample, divided into subgroups based on type of hyperthyroidism, gender and age.
The table shows that the proportions of men and women were similar for both groups, but that the TMG patients were older (p < 0.05).
The assessment of the overall efficacy of treatment at one year after 131 I administration showed that a euthyroid status was achieved in 94%, hypothyroidism was observed in 3%, while persistence or recurrence of hyperthyroidism in 3% of patients with autonomous toxic nodules. In toxic multinodular goitre patients however the efficacy was slightly lower (p < 0.05) and amounted to 89%, 4%, 7% respectively. This outcome meant that further treatment was necessary only in 7% of TMG patients and in 3% of ATN cases ( Figure 4 ).
As the time after radioiodine administration elapses, the percentage of hypothyroid patients increases. And thus, 3 years after 131 I administration the proportion of such patients in the ATN subgroup was 9%, while 5 years after the treatment it rose to 11%. In the TMG subgroup, the percentage was 11% and 16% respectively. This amounts to an average annual increase of 1.6% (ATN) and 2.4% (TMG) in hypothyroidism among the study sample ( Figure 5 ). Tables 2 and 3 show that neither gender nor age had a significant influence on the final outcome of hyperthyroidism treatment.
The best therapeutic results, i.e. the highest euthyroidism rate and the lowest persistent hyperthyroidism rate, were obtained in patients with autonomous adenoma and with considerable suppression of healthy tissue surrounding the nodule.
It was also established that a correlation exists between therapeutic outcome and the effective half-life of 131 I. The highest efficacy was obtained in patients treated with radioiodine which had at least a 7-day effective half-life.
The lowest proportion of hypothyroidism and, at the same time, the lowest efficacy was observed in patients with large and very large glands (above 60 ml). levels and the volume of the thyroid gland. To be more precise, the chances of achieving euthyroidism grow 3.6 times when radioiodine uptake in nodule is moved up one level, 2-fold when T 24 and T eff.
concentrations rise, and 1.5 times when the volume of the thyroid increases (Table 4) . Whereas, hypothyroidism is most likely to develop when the rate of radioiodine uptake in nodules is low. With a 1% rise in the rate of radioiodine uptake in nodule, the probability of hypothyroidism occurring after treatment drops 0.31 times ( Table 5 ).
The primary objective of radioiodine therapy is to eliminate
hyperthyroidism, but what is significant for patients is the quickness of therapeutic effect. First and foremost, we take steps to prepare patients for the 131 I treatment in such a way that after the radioiodine capsule is ingested, the radiation energy is absorbed entirely, or primarily, by autonomous nodules. We regard achieving the lowest possible TSH serum value as an essential part of patient preparation. Our Department treats only patients with TSH < 0.1 IU/ml, which minimises iodine uptake and potential radiation-induced damage of the tissue surrounding the nodules [2] . The prerequisite of low TSH is frequently overlooked in other studies. What seems to further confirm this observation is the fact that those studies recommend discontinuation of antithyroid drugs merely days before the planned administration of radioiodine. As is well known, antithyroid drugs medications first of all inhibit the function of autonomous thyroid nodules and, as a consequence, enhance the action of the pituitary gland, which results in elevated TSH secretion thereby stimulating radioiodine uptake in normal tissue and leads to needless damage or destruction. That is why the outcomes presented in the mentioned studies are relatively worse than ours. Namely, they report a higher percentage of hypothyroid patients, amounting even to 45% at one year after radioiodine therapy in our Department, hypothyroidism was observed in 3% of ATN patients and 4% of TMG patients.
Proper qualification of patients with severe hyperthyroid symptoms should involve bringing the levels of the thyroid hormones (thyroxine and triiodothyronine) within the normal range. For this reason, some cases require preliminary but short-term (2-3 days) treatment with antithyroid drugs in order to lower the concentrations of fT 4 and fT 3 in serum and in the thyroid gland itself, but without increasing the TSH blood level. With this condition fulfilled, there is a lower risk of early, transient exacerbation of hyperthyroidism caused by an increased release of thyroid gland hormones from radioactively damaged thyreocytes into the blood stream [2] .
When qualifying patients for treatment, it is indispensable that the scintigraphy of the thyroid gland is performed, as well as iodine uptake tests, the results of which can be used for calculating the effective half-life for Marinelli's formula [20] . This kind of diagnostic allows precise imaging of the gland, as well as a quantitative assessment of its functioning. It also enables the physician to calculate the extent to which iodine uptake is prevented in the tissue adjacent to the nodules. The information is essential for establishing the target thyroid absorbed radiation dose, i.e. with only a small margin of surrounding tissue [1] . The maximum absorbed dose adopted in our Department is 400 Gy for both autonomous and multinodular goitre, which is a commonly accepted value [8, 21, 22] . In those patients whose normal tissue adjacent to nodules is not fully suppressed (II and III degree in the Department), we used appropriately lower absorbed doses. The above findings seem to be corroborated by the fact that the greatest proportion of euthyroidism was observed in patients with the 1st degree suppression of normal tissue, both in the case of solitary and multinodular goitres. Therefore, Okosieme et al.'s claim that scintigraphy of the thyroid gland which images the distribution of radioiodine in the thyroid tissue does not have any bearing on the outcome of treatment seems to stem from inadequate understanding of the significance of radioisotopic diagnostic investigation for radioiodine therapy of thyroid disorders [3] .
The evaluation of the effective half-life and iodine uptake in the thyroid is also crucial because the therapeutic activity of a given absorbed dose is inversely proportional to the values of these parameters (as both of them are in the denominator of the modified Marinelli formula). In other words, when the values of iodine uptake and effective half-life drop, the therapeutic activity of 131 I grows. To avoid exceeding national limits for therapeutic activity (800 MBq), we assumed that the lower threshold for iodine uptake in radioiodine therapy patients is 20%, since below this value therapeutic activities calculated by the Marinelli formula -even for medium-sized glands -were frequently higher than 800 MBq [23] .
The effective half-life of radioiodine depends on its biological half-life. It is usually the case that the less acute hyperthyroidism was before treatment, the longer the biological half-life of radioiodine. Thus the values of thyroxine and triiodothyronine in patients who are qualified for treatment in our Department are usually only slightly above the norm. In both analysed subgroups, T eff. va- Original lues were not lower than 5 days. Having analysed the above data, and having considered the work of such researchers as Gupta and Abos, who use fixed therapeutic doses and do not perform iodine uptake tests in their patients, it can be concluded that one of the reasons for lower treatment efficacy (78% of euthyroidism, 90% in our institution) in patients treated in this way is the fact that the target absorbed doses are not correlated with the iodine uptake capacity, iodine effective half-life in the thyroid or the volume of the gland [17] . Therefore, in the case of post-therapy hypothyroidism, the thyroid absorbed dose was probably too high, while in hyperthyroid patients it might have been too low.
Moreover, when analysing the results we noticed that, contrary to expectations, moderate enlargement of the thyroid gland (i.e. by 30-60 ml) does not adversely affect the efficacy of radiotherapy, but even enhances it (Table 4 ). This can be explained by the fact that, given mild thyroid enlargement after radiotherapy, the amount of glandular tissue damaged by the first dose of 131 I is proportionately greater, which, to a certain extent, prevents hypothyroidism and increases the efficacy of toxic goiter treatment.
Conclusions
Hyperthyroid patients with nodular goitres qualified for radioiodine therapy should have the lowest possible TSH blood levels in order to minimise the risk of post-radiation damage to the gland tissue surrounding the nodule.
Serum concentrations of fT 3 and fT 4 before treatment should be around the upper limit of normal so as to minimise possible exacerbation of transitory hyperthyroidism resulting from a sudden release of hormones from the damaged thyreocytes.
In each case, scintigraphy and iodine uptake tests should be carried out, and the percentage of radioiodine uptake in nodules established, relative to the uptake in the entire gland. Only the knowledge of this ratio makes it possible to determine the appropriate absorbed radiation dose.
